ONYX Pharmaceuticals Inc. (ONXX)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

249 E. GRAND AVE. SOUTH SAN FRANCISCO, CA 94080

ONYX Pharmaceuticals Inc discovers and develops novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company's lead drug candidate, sorafenib, is in Phase III clinical development.

View SEC Filings from ONXX instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ONXX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ONXX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LASOWSKI JUERGEN EVP, CORP. DEV & STRATEGY

  • Officer
No longer subject to file 2013-10-01 0

WIERENGA WENDALL

  • Director
No longer subject to file 2013-10-01 0

TORLEY HELEN EVP, CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2013-10-01 0

SHEMA SUZANNE M EVP,GC AND CORP. SECRETARY

  • Officer
No longer subject to file 2013-10-01 0

FOSTER-CHEEK KAYE I SVP, GLOBAL HUMAN RESOURCES

  • Officer
No longer subject to file 2013-10-01 0

FUST MATTHEW K EVP & CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2013-10-01 0

WOOD JULIANNA R VP, PUBLIC AFFAIRS

  • Officer
No longer subject to file 2013-10-01 0

WIGGANS THOMAS G

  • Director
No longer subject to file 2013-10-01 0

COLES N ANTHONY CHAIRMAN & CEO

  • Officer
  • Director
No longer subject to file 2013-10-01 0

RINGO WILLIAM R

  • Director
No longer subject to file 2013-10-01 0

NEVINNY CORINNE H

  • Director
No longer subject to file 2013-10-01 0

LUNDBERG MAGNUS

  • Director
No longer subject to file 2013-10-01 0

GRILLO LOPEZ ANTONIO J

  • Director
No longer subject to file 2013-10-01 0

GODDARD PAUL

  • Director
No longer subject to file 2013-10-01 0

CAGNONI PABLO J EVP, GLOBAL R&D AND TECH OPS

  • Officer
No longer subject to file 2013-10-01 0

LOVE TED W EVP, R&D AND TECH. OPERATIONS

  • Officer
77,756 2012-07-25 0

OSBORN JOHN E SVP, GLOBAL CORPORATE AFFAIRS

  • Officer
11,000 2012-06-01 0

BREGE LAURA EVP, CORPORATE AFFAIRS

  • Officer
39,670 2011-10-14 0

BATLIN JUDY A VP, ORG LEARNING, DVLPMNT & HR

  • Officer
15,148 2010-03-31 0

KAUFFMAN MICHAEL CHIEF MEDICAL OFFICER

  • Officer
9,000 2010-02-09 0

FUCHS HENRY J EVP & CHIEF MEDICAL OFFICER

  • Officer
14,891 2008-11-18 0

SCHAFER GREGORY W CFO

  • Officer
9,747 2008-09-18 0

GIOTTA GREGORY J VP & CHIEF LEGAL COUNSEL

  • Officer
3,833 2008-08-14 0

KENNEY EDWARD F EVP, CHIEF BUSINESS OFFICER

  • Officer
28,158 2008-02-19 0

RENTON HOLLINGS PRESIDENT AND CEO

  • Officer
  • Director
113,469 2008-02-19 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments